|
|
Volumn 5, Issue 4, 2004, Pages 333-335
|
|
Going global in R and D. Economics and politics are making offshoring an increasingly attractive option for biobusinesses
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADALIMUMAB;
ERYTHROPOIETIN;
ETANERCEPT;
NEW DRUG;
ARTHRITIS;
BIOENGINEERING;
BIOINFORMATICS;
BIOMEDICINE;
BIOTECHNOLOGY;
COMMERCIAL PHENOMENA;
COST BENEFIT ANALYSIS;
COST CONTROL;
DRUG INDUSTRY;
DRUG MANUFACTURE;
ECONOMIC ASPECT;
HUMAN;
INVESTMENT;
MEDICAL RESEARCH;
NOTE;
POLITICS;
PRIORITY JOURNAL;
PROFIT;
PROSPECTIVE PRICING;
RHEUMATOID ARTHRITIS;
OUTSOURCED SERVICES;
RESEARCH;
|
|
EID: 2442585668
PISSN: 1469221X
EISSN: None
Source Type: Journal
DOI: 10.1038/sj.embor.7400135 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|